Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $18.7900 (-7.48%) ($18.4500 - $20.2800) on Wed. Sep. 25, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.08% (three month average) | RSI | 35 | Latest Price | $18.7900(-7.48%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -2% a day on average for past five trading days. | Weekly Trend | IOVA declines -1.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(49%) XBI(48%) ARKG(47%) IWO(44%) ARKK(42%) | Factors Impacting IOVA price | IOVA will decline at least -1.54% in a week (0% probabilities). VIXM(-28%) VXX(-15%) UUP(-9%) TLT(-2%) TBT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.54% (StdDev 3.08%) | Hourly BBV | 0 () | Intraday Trend | -7.3% | | | |
|
Resistance Level | $20.61 | 5 Day Moving Average | $20.1(-6.52%) | 10 Day Moving Average | $20.54(-8.52%) | 20 Day Moving Average | $20.61(-8.83%) | To recent high | -27.7% | To recent low | 0% | Market Cap | $2.752b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |